Search results
Background and objective: Although older patients with coronavirus disease 2019 (COVID-19) are at the high risk of exacerbation that requires treatment with remdesivir, the safety of this medication is unclear in clinical practice, especially among older patients.
The FDA granted EUA to molnupiravir on December 23, 2021, for the treatment of mild-to-moderate COVID-19 in adults (≥18 years) who are at high risk for progression to severe COVID-19, including hospitalization or death.
16 maj 2020 · The median age of study patients was 65 years (IQR 56–71); sex distribution was 89 (56%) men versus 69 (44%) women in the remdesivir group and 51 (65%) versus 27 (35%) in the placebo group (table 1). The most common comorbidity was hypertension, followed by diabetes and coronary heart disease.
3 paź 2024 · Fewer than one half of adults aged ≥65 years with an outpatient COVID-19 diagnosis received a recommended COVID-19 antiviral medication, including 48% among adults aged 65–74 years, 44% among those aged 75–89 years, and 35% among those aged ≥90 years.
29 lis 2021 · By conducting a comprehensive systematic review including unpublished data (where available), we expect to be able to provide valuable information for patients and clinicians about the benefits and harms of remdesivir for the treatment of Covid-19.
15 gru 2021 · Real-World Effectiveness of Remdesivir in Adults Hospitalized With Coronavirus Disease 2019 (COVID-19): A Retrospective, Multicenter Comparative Effectiveness Study | Clinical Infectious Diseases | Oxford Academic. Journal Article.
30 lip 2020 · Recommendation 1 We suggest remdesivir rather than no remdesivir in patients with severe covid-19 Usual supportive care Remdesivir or 100 mg intravenously daily for 5-10 days No remdesivir Strong Weak Weak Strong Resource limited settings. Evidence profile. Individual considerations.
